National cohort for pediatric autoimmune cytopenia
Official title: "French National Cohort of Patients With Pediatric-onset of Autoimmune Cytopenia (OBS'CEREVANCE Cohort)"
Run by University Hospital, Bordeaux · NCT05937828 · Data updated 2026-11-12
This study is trying to gather information about children with autoimmune blood disorders to see how they do over time and what treatments work best for them.
Quick facts
| Study type | Observational |
|---|---|
| Ages | Any age to 17 Years |
| Sex | All |
| Enrollment | 3500 (estimated) |
| Sponsor | University Hospital, Bordeaux Academic / other |
| Locations | 9 sites (Amiens and 8 other locations) |
| Status | Recruiting |
| Started | September 1, 2010 |
| Main results expected | December 31, 2029 |
| Study ends | December 31, 2029 |
| Registry record updated | July 10, 2023 |
| Trial ID | NCT05937828 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are children diagnosed with ITP, AIHA, or Evans Syndrome before the age of 18.
✕Probably not a fit
Patients whose legal representatives oppose data collection will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
OBS'CEREVANCE is a national prospective cohort initiated in 2004 that focuses on pediatric patients diagnosed with autoimmune cytopenias, including Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia (AIHA), and Evans Syndrome. The cohort, supported by 30 pediatric hematologic centers across France, aims to collect real-world data to understand the long-term health outcomes of these patients, identify genetic factors, and evaluate the benefit-risk balance of various treatments. This comprehensive database serves as a resource for care, education, and research in the field of pediatric autoimmune cytopenias.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of pediatric autoimmune cytopenias, potentially enhancing treatment outcomes for affected patients.
How similar studies have gone: Other studies focusing on pediatric autoimmune conditions have shown promise, but this cohort represents a unique and extensive approach to understanding these rare diseases.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of ITP, AIHA, Evans Syndrome * Onset before the age of 18 Exclusion Criteria: * Opposition of legal representative or to data collection
Where it's running
-
CHU Amiens Picardie Service d' Onco-Immuno-Hématologie Pédiatrique
Amiens, France Recruiting -
CHU d'Angers Unité d'Hémato-Oncologie Pédiatrique
Angers, France Recruiting -
BESANCON CHU de Besançon Hôpital Jean MINJOZ Unité d'Hémato-Oncologie Pédiatrique, Pédiatrie 1
Besançon, France Recruiting -
CHU de Bordeaux - Unité d'Hématologie et d'Oncologie pédiatrique
Bordeaux, France Recruiting -
CHU BREST Hôpital Morvan Unité d'Onco-Hématologie
Brest, France Recruiting -
CHU de Caen Unité d'Onco-Hématologie
Caen, France Recruiting
Show 3 more locations
-
CHU de Clermont Ferrand
Clermont-Ferrand, France Recruiting -
APHP Hôpital Bicêtre Service de Pédiatrie générale
Paris, France Recruiting -
CH de Cornouaille Service de Pédiatrie
Quimper, France Recruiting
Study contacts
- Principal investigator: Nathalie ALADJIDI, MD — University Hospital, Bordeaux
- Study coordinator: Nathalie ALADJIDI, MD
- Email: nathalie.aladjidi@chu-bordeaux.fr
- Phone: +33 557820261
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
UCAR-T cells targeting CD19 and BCMA for autoimmune blood disorders
This treatment tests an off-the-shelf UCAR-T cell therapy that targets CD19 and BCMA to try to treat adults with antibody-driven blood disorders like ITP, autoimmune hemolytic anemia, and Evans syndrome.
-
CM336 treatment for relapsed or refractory autoimmune cytopenia
This trial will test whether CM336, a BCMA/CD3 bispecific antibody given by injection, can help adults with relapsed or refractory autoimmune cytopenias such as ITP, AIHA, or Evans syndrome.
-
Evaluation of diagnosis and treatment for autoimmune cytopenias
This study is trying to understand how autoimmune cytopenias are diagnosed and treated, looking at different tests and treatments to see what works best for patients.
-
Biological bank for patients with autoimmune cytopenia
This study is setting up a collection of biological samples from patients with autoimmune cytopenia to help researchers learn more about these conditions and find better treatments.
-
Registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France
This study is collecting information from adults in France who have recently been diagnosed with immune thrombocytopenia or autoimmune hemolytic anemia to better understand these conditions and how well different treatments work in real life.
-
F182112 in relapsed/refractory autoimmune hemolytic anemia
A small early study tests F182112 as a single treatment for adults with AIHA that has not responded to other therapies, to see if it’s safe and what dose works best.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.